{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:38Z","timestamp":1793214638546,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.vaccine.2012.11.060","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T08:45:23Z","timestamp":1366188323000},"page":"B176-B183","source":"Crossref","is-referenced-by-count":31,"special_numbering":"S2","title":["Developing Countries Vaccine Manufacturers Network: Doing good by making high-quality vaccines affordable for all"],"prefix":"10.1016","volume":"31","author":[{"given":"Sonia","family":"Pagliusi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana C.C.","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahima","family":"Datla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morena","family":"Makhoana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendra","family":"Suhardono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gutla V.J.A.","family":"Harshavardhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.11.060_bib0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0264-410X(01)00454-6","article-title":"Developing Country Vaccine Manufacturers Network (DCVMN), 26\u201327 April 2001, Bandung, Indonesia","volume":"20","author":"Poeloengan","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.11.060_bib0010","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.vaccine.2008.01.034","article-title":"The developing countries vaccine manufacturers\u2019 network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries","volume":"26","author":"Jadhav","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.11.060_bib0015","unstructured":"Measles, Key facts, Fact sheet No. 286, April 2012. Available at http:\/\/www.who.int\/mediacentre\/factsheets\/fs286\/en\/index.html."},{"key":"10.1016\/j.vaccine.2012.11.060_bib0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4161\/hv.3.4.4061","article-title":"A multicenter, prospective, open-label, non-comparative study to evaluate the immunogenicity and tolerance of a new, fully liquid pentavalent vaccine (DTwP-HepB-Hib vaccine)","volume":"3","author":"Ali","year":"2007","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2012.11.060_bib0025","unstructured":"Information available at http:\/\/www.unicef.org\/supply\/files\/12_01_13_DTP-HepB-Hib.pdf, consulted on July 15th, 2012."},{"key":"10.1016\/j.vaccine.2012.11.060_bib0030","unstructured":"Connecting for a cause. DCVMN brochure. Available at www.dcvmn.org."},{"key":"10.1016\/j.vaccine.2012.11.060_bib0035","unstructured":"Global Allert and Response: meningococcal diseases: http:\/\/www.who.int\/csr\/don\/archive\/disease\/meningococcal_disease\/en\/index.html."},{"key":"10.1016\/j.vaccine.2012.11.060_bib0040","unstructured":"WHO report: Viral Hepatitis in the WHO South East Asia Region. http:\/\/www.searo.who.int\/LinkFiles\/Diarrhoea,_ARI_and_hepatitis_SEA-CD-232.pdf."},{"key":"10.1016\/j.vaccine.2012.11.060_bib0045","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(10)61030-6","article-title":"Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial","volume":"376","author":"Zhu","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2012.11.060_bib0050","unstructured":"World Health Organization, Water-related diseases, Japanese Encephalitis. http:\/\/www.who.int\/water_sanitation_health\/diseases\/encephalitis\/en\/."},{"key":"10.1016\/j.vaccine.2012.11.060_bib0055","unstructured":"http:\/\/www.nhs.uk\/Conditions\/Japanese-encephalitis\/Pages\/Beforeyougo.aspx."},{"key":"10.1016\/j.vaccine.2012.11.060_bib0060","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1128\/CVI.00339-08","article-title":"Immunogenicity of a whole-cell pertussis vaccine with low lipopolysaccharide content in infants","volume":"16","author":"Zorzeto","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2012.11.060_bib0065","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1016\/j.vaccine.2009.04.047","article-title":"Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice","volume":"27","author":"Quintilio","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.11.060_bib0070","doi-asserted-by":"crossref","first-page":"8974","DOI":"10.1016\/j.vaccine.2011.09.040","article-title":"A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems","volume":"8","author":"Precioso","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.11.060_bib0075","unstructured":"India records one year without polio cases. WHO Media Centre, News Release, 12 January 2012. http:\/\/www.who.int\/mediacentre\/news\/releases\/2012\/polio_20120113\/en\/."},{"key":"10.1016\/j.vaccine.2012.11.060_bib0080","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1179\/136485906X97354","article-title":"Eradicating polio: today's challenges and tomorrow's legacy\u201d","volume":"100","author":"Aylward","year":"2006","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.vaccine.2012.11.060_bib0085","unstructured":"WHO facilitates new polio vaccine technology transfer http:\/\/www.polioeradication.org\/tabid\/461\/iid\/188\/Default.aspx, call for expressions of interest (EoI). Developing Sabin-inactivated polio vaccine (sIPV) 2012. Available at: http:\/\/www.polioeradication.org\/Portals\/0\/Document\/Research\/EOI_POL_20120427.pdf."},{"key":"10.1016\/j.vaccine.2012.11.060_bib0090","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"Bakker","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.11.060_bib0095","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1086\/651611","article-title":"Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba","volume":"201","author":"Resik","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.11.060_bib0100","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2471\/BLT.11.090175","article-title":"The WHO research agenda for influenza: two years later","volume":"90","author":"Perdue","year":"2012","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2012.11.060_bib0105","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1098\/rstb.2011.0102","article-title":"Towards universal influenza vaccines","volume":"366","author":"Osterhaus","year":"2011","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.vaccine.2012.11.060_bib0110","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1586\/erv.11.82","article-title":"The future of cell culture-based influenza vaccine production","volume":"10","author":"Perdue","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2012.11.060_bib0115","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1016\/j.vaccine.2011.04.124","article-title":"An international technology platform for influenza vaccines","volume":"29","author":"Hendriks","year":"2011","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2012.11.060_bib0120","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.1016\/j.vaccine.2011.04.127","article-title":"Influenza vaccine production for Brazil: a classic example of successful North-South bilateral technology transfer","volume":"29","author":"Miyaki","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.11.060_bib0125","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/erv.09.23","article-title":"Reaching international GMP standards for vaccine production: challenges for developing countries","volume":"8","author":"Milstien","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2012.11.060_bib0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.biologicals.2011.09.013","article-title":"Public vaccine manufacturing capacity in the Latin American and Caribbean region: current status and perspectives","volume":"40","author":"Cortes Mde","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2012.11.060_bib0135","unstructured":"UNICEF procurement and supply overview; 2011. http:\/\/www.unicef.org\/supply\/files\/UNICEF_Supply_Annual_Report_2011_web.pdf."},{"key":"10.1016\/j.vaccine.2012.11.060_bib0140","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.biologicals.2009.02.009","article-title":"Emerging markets & emerging needs: developing countries vaccine manufacturers\u2019 perspective & its current status","volume":"37","author":"Jadhav","year":"2009","journal-title":"Biologicals"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1201701X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1201701X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T18:26:52Z","timestamp":1539714412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1201701X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":28,"alternative-id":["S0264410X1201701X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.11.060","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}